Liquidia appoints Dr. Rajeev Saggar as CMO, succeeding Dr. Tushar Shah

Liquidia Corp

Dr. Tushar Shah terminated as CMO effective June 15, 2022; severance agreement being finalized.
Dr. Rajeev Saggar appointed CMO effective July 18, 2022; previously VP Clinical Development at Theravance Biopharma.
Dr. Saggar receives $475k base salary, 40% target bonus, $50k sign-on bonus, and equity grants (200k option + RSUs worth $350k).
Dr. Saggar has over 20 years pulmonology experience and served as PI in pivotal INSPIRE study of YUTREPIA.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Tushar Shah

Chief Medical Officer

LQDA · Liquidia Corp

Effective: 2022-06-15
Filed: June 22, 2022, 7:59 PM ET

Effective June 15, 2022, Tushar Shah, M.D.’s employment with Liquidia Corporation, a Delaware corporation (the “Company”) as the Company’s Chief Medical Officer terminated.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Tushar Shah was terminated as Chief Medical Officer at Liquidia Corp.

Action: terminated
Role: Chief Medical Officer

Exact text from the filing

Effective June 15, 2022, Tushar Shah, M.D.’s employment with Liquidia Corporation, a Delaware corporation (the “Company”) as the Company’s Chief Medical Officer terminated.

View on SEC.gov

Liquidia Corp filing history →

Source: SEC EDGAR

accession 0001104659-22-073264

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.